abs57.txt	purpose		male	breast	cancer	(bc)	is	rare		representing	approximately	1%	ofcancers	that	occur	in	men	and	approximately	1%	of	all	bcs	worldwide		because	malebc	is	rare		not	much	is	known	about	the	disease		and	treatment	recommendationsare	typically	extrapolated	from	data	available	from	clinical	trials	enrollingfemale	bc	patients	methods		we	review	the	epidemiology		risk	factors		prognosis		and	the	variedmolecular	and	clinicopathologic	features	that	characterize	male	bc		in	addition	we	summarize	the	available	data	for	the	use	of	systemic	therapy	in	the	treatmentof	male	bc	and	explore	the	ongoing	development	of	targeted	therapeutic	agents	forthe	treatment	of	this	subgroup	of	bcs	results		there	are	important	biological	differences	between	male	and	female	bc	male	bc	is	almost	exclusively	hormone	receptor	positive	(+)		including	theandrogen	receptor	(ar)		and	is	associated	with	an	increased	prevalence	of	brca2germline	mutations		especially	in	men	with	increased	risk	for	developinghigh-risk	bc		additional	research	is	warranted	to	better	characterize	male	bc		toaccomplish	this		a	multi-national	consortium	approach		such	as	the	internationalmale	breast	cancer	program		is	needed	in	response	to	the	scarcity	of	patients	this	approach	allows	the	pooling	of	information	from	a	large	number	of	men	withbc	and	the	creation	of	registries	for	future	therapeutic-focused	clinical	trials	conclusions		given	the	unique	biology	of	bc	in	men		promising	new	therapeutictargets	are	currently	under	investigation		including	the	use	of	poly-adp-ribosepolymerase	inhibitors	or	ar-targeted	agents	either	as	monotherapy	or	incombination	with	other	agents	
